Epigenetics Industry Will Generate $4,279M in 2018, According to a New Study on ASDReports

Thursday 7 August 2014, Amsterdam

The new report now availabe on ASDReports, forecasts the worldwide epigenetics market will achieve revenues of $4,279 million in 2018. That industry will generate $2,501 million in 2014, according to Epigenetic R&D, Therapies and Diagnostics: Industry and Market Prospects 2014-2024, published in June 2014. Visiongain is a business information publisher and consultancy in London, UK.

That new study predicts the global epigenetics industry will expand fast during the forecast period 2014 to 2024, especially during the first half. Growth in the industry’s revenues will be stimulated by the launch of new therapies, which will be predominantly HDAC inhibitors, along with new diagnostics. An ageing global population and rising cancer incidences will contribute to growth of the epigenetics market. The expected growth in the therapies and diagnostics submarkets will be offset by competing technologies and some therapies’ patent expiries.

Shusmita Sen, a pharmaceutical industry analyst said: “The epigenetics industry will be growing with a double digit compound annual growth rate over the next 10 years. So far, four therapies have been approved in the US. By 2024, we expect at least ten new therapies to be launched in the same market, mostly for cancer indications. We predict the US will account for more than 50% of the global epigenetics market by 2024. The majority of the pipeline therapies are focusing on cancer indications; however some therapies have demonstrated potential beyond cancer. For example Zolinza (vorinostat) has demonstrated clearing latent HIV from patients receiving other treatments. Other therapies are also targeting mental health, neuropsychiatric conditions and ageing and metabolic disorders.

“Leading pharmaceutical companies are using licensing agreements with biotechs. We expect more deals to take place during the next 10 years, considering the R&D pipeline of investigational HDAC inhibitors and some promising new targets recently discovered. The costs of epigenetic technologies have significantly decreased, and this has enabled small scale researchers to carry out more research in epigenetics, which will contribute to the growing list of investigational epigenetic drugs. There is also need for improved bioinformatics to aid analysis of data obtained through epigenetic technologies.

“Epigenetic diagnostics formed the smallest submarket in 2013; it will give the fastest growing segment from 2014 to 2024. Epigenetic diagnostic developers are currently challenged with receiving approvals from the FDA. The CE approved diagnostics have produced low revenue in Europe, causing companies to take different marketing strategies in those regions. Thus future growth of the epigenetic diagnostics market will heavily rely on FDA approvals.”

The investigation shows revenue forecasts to 2024 at overall world market, submarket, product and national level.

That study gives individual revenue predictions to 2024 for three epigenetic submarkets at world level:

• Therapies
• Technologies for research
• Diagnostics.

Also that report analyses leading regional markets for epigenetic therapies, technologies and diagnostics. It gives revenue forecasts to 2024 for the US, the EU (including the five leading countries), Japan, Canada and the BRIC nations (grouped analysis). It examines and compares products in research and development (R&D) and leading companies. It also gives revenue forecasts to 2024 for six drugs. Overall the analysis shows 72 tables, 57 charts and an interview.